Shares of Johnson & Johnson
gained 1.2% in after-hours buying and selling on Thursday after the corporate introduced that it had submitted an utility for an emergency use authorization to the Food and Drug Administration for its COVID-19 vaccine candidate. The experimental single-dose COVID vaccine was 72% effective at stopping symptomatic illness within the U.S. arm of the Phase 3 scientific trial, in accordance with findings launched Jan. 29. The FDA is predicted to schedule a gathering of an advisory committee that may vote on whether or not the advantages of the vaccine outweigh the dangers, as was executed previous to the emergency use authorizations of BioNTech SE
and Moderna Inc.’s
COVID-19 vaccines. The firm additionally mentioned Thursday that its vaccine will be saved for 2 years at destructive 4 levels Fahrenheit in most traditional fridges, and that it will possibly present 100 million doses of its vaccine candidate within the U.S. within the first half of 2021. J&J’s inventory has gained 6.8% over the previous 12 months, whereas the broader S&P 500
is up 17.9%.